News
VNRX
0.6480
+5.69%
0.0349
Weekly Report: what happened at VNRX last week (1216-1220)?
Weekly Report · 2d ago
Weekly Report: what happened at VNRX last week (1209-1213)?
Weekly Report · 12/16 12:06
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
PR Newswire · 12/12 13:00
VolitionRX Is Maintained at Buy by D. Boral Capital
Dow Jones · 12/10 14:29
VolitionRX Price Target Maintained With a $5.00/Share by D. Boral Capital
Dow Jones · 12/10 14:29
D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target
Benzinga · 12/10 14:20
VolitionRx’s Nu.Q cancer test shows efficacy in lung cancer detection
TipRanks · 12/10 13:20
Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening
PR Newswire · 12/10 13:00
Weekly Report: what happened at VNRX last week (1202-1206)?
Weekly Report · 12/09 12:04
Weekly Report: what happened at VNRX last week (1125-1129)?
Weekly Report · 12/02 12:05
Weekly Report: what happened at VNRX last week (1118-1122)?
Weekly Report · 11/25 11:54
Benchmark Reiterates Hold on VolitionRX
Benzinga · 11/22 14:40
VolitionRX (VNRX) Gets a Hold from Benchmark Co.
TipRanks · 11/22 12:02
Weekly Report: what happened at VNRX last week (1111-1115)?
Weekly Report · 11/18 11:50
VolitionRx Posts Strong Q3 Growth and Strategic Advances
TipRanks · 11/16 03:55
VolitionRX Is Maintained at Buy by D. Boral Capital
Dow Jones · 11/15 22:05
VolitionRX Price Target Maintained With a $5.00/Share by D. Boral Capital
Dow Jones · 11/15 22:05
D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target
Benzinga · 11/15 21:55
VOLITIONRX LIMITED QUARTERLY REPORT ON FORM 10-Q FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024
Press release · 11/15 01:05
More
Webull provides a variety of real-time VNRX stock news. You can receive the latest news about Volitionrx through multiple platforms. This information may help you make smarter investment decisions.
About VNRX
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.